Fintel on MSN2d
Leerink Partners Downgrades Agios Pharmaceuticals (AGIO)Fintel reports that on September 27, 2024, Leerink Partners downgraded their outlook for Agios Pharmaceuticals (NasdaqGS:AGIO ...
Leerink Partners analyst Faisal Khurshid said that he likes the “risk/reward” profile of Immunic’s CALLIPER trial readout, ...
In a report released on September 25, Marc Goodman from Leerink Partners maintained a Hold rating on Alkermes (ALKS – Research Report).
Regeneron (REGN) stock was downgraded by Leerink after a court ruling that favored Amgen's (AMGN) plans to introduce a biosimilar for REGN's Eylea. Read more here.
On Friday, Lexicon Pharmaceuticals Inc (LXRX) stock saw a modest uptick, ending the day at $1.6 which represents a slight increase of $0.06 or 3.90% from the prior close of $1.54. The stock opened at ...
Leerink Partners analyst Puneet Souda reiterated a Buy rating on Quanterix (QTRX – Research Report) today. The company’s shares ...
Equities researchers at Leerink Partners initiated coverage on shares of MannKind (NASDAQ:MNKD – Get Free Report) in a research report issued to clients and investors on Monday, Marketbeat reports ...
On Friday, Teladoc Health Inc (TDOC) stock saw a modest uptick, ending the day at $8.46 which represents a slight increase of $0.05 or 0.59% from the prior close of $8.41. The stock opened at $8.58 ...
Fintel reports that on September 24, 2024, Leerink Partners downgraded their outlook for Regeneron Pharmaceuticals (WBAG:REGN) from Outperform to Market Perform. There are 2,433 funds or ...
Leerink Partners has initiated coverage on shares of MannKind (NASDAQ:MNKD) Corporation (NASDAQ: MNKD), assigning an Outperform rating and setting a price target of $8.00. The firm anticipates ...
Leerink Partners analyst Mani Foroohar has maintained their bullish stance on ENGN stock, giving a Buy rating on September 27. Mani Foroohar ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback